High Growth Tech Stocks To Watch In October 2024

In This Article:

The United States market has shown robust performance with a 1.2% increase over the last week and a remarkable 32% rise in the past year, while earnings are projected to grow by 16% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that not only capitalize on current technological trends but also demonstrate strong potential for sustained earnings growth.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

20.86%

27.98%

★★★★★★

Sarepta Therapeutics

23.67%

44.28%

★★★★★★

TG Therapeutics

28.39%

43.54%

★★★★★★

Ardelyx

27.19%

66.44%

★★★★★★

Invivyd

42.91%

70.39%

★★★★★★

Amicus Therapeutics

20.32%

62.45%

★★★★★★

AsiaFIN Holdings

60.53%

81.55%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

Travere Therapeutics

27.16%

69.88%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 253 stocks from our US High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Cinemark Holdings

Simply Wall St Growth Rating: ★★★★★☆

Overview: Cinemark Holdings, Inc., along with its subsidiaries, operates in the motion picture exhibition industry and has a market capitalization of approximately $3.28 billion.

Operations: Cinemark Holdings generates revenue primarily from its U.S. operations, contributing $2.24 billion, while its international segment adds $596.80 million.

Cinemark Holdings, transitioning into profitability this year, shows a promising trajectory with an expected earnings growth of 28.1% annually, outpacing the U.S. market average of 15.9%. Despite a challenging comparison to the broader Entertainment industry's growth rate of 3.8%, Cinemark's strategic focus on enhancing customer experience and expanding its digital engagement platforms could bolster future revenue streams, which are projected to grow at 8.9% per year—slightly above the market forecast of 8.8%. Moreover, with a robust forecast Return on Equity of 41.6% in three years' time and positive free cash flow, Cinemark is positioning itself as a resilient contender in the evolving entertainment landscape despite recent dips in quarterly earnings and revenue figures reported in September and August conferences.

NYSE:CNK Revenue and Expenses Breakdown as at Oct 2024
NYSE:CNK Revenue and Expenses Breakdown as at Oct 2024

Evolent Health

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Evolent Health, Inc., through its subsidiary Evolent Health LLC, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States with a market capitalization of approximately $3.01 billion.